Boehringer Ingelheim Corporation to Present Highly Anticipated Data From Landmark Tiospir™ Trial, and Their Respiratory Pipeline Products in COPD, Asthma, IPF and Lung Cancer at ERS 2013

Published: Sep 03, 2013

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!


or media outside the UK, US and Canada

•Results of COPD Phase III landmark trial TIOSPIR™ comparing safety and efficacy of SPIRIVA® Respimat® versus SPIRIVA® HandiHaler®

•Phase III trial results on investigational compound olodaterol* Respimat® as once-daily maintenance bronchodilator monotherapy in COPD

Help employers find you! Check out all the jobs and post your resume.

Back to news